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Abstract 
Background: Despite recent efforts and successes in reducing the malaria burden globally, this infection still 
accounts for an estimated 212 million clinical cases, 2 million severe malaria cases, and approximately 429,000 deaths 
annually. Even with the routine use of effective anti-malarial drugs, the case fatality rate for severe malaria remains 
unacceptably high, with cerebral malaria being one of the most life-threatening complications. Up to one-third of 
cerebral malaria survivors are left with long-term cognitive and neurological deficits. From a population point of 
view, the decrease of malaria transmission may jeopardize the development of naturally acquired immunity against 
the infection, leading to fewer total cases, but potentially an increase in severe cases. The pathophysiology of severe 
and cerebral malaria is not completely understood, but both parasite and host determinants contribute to its onset 
and outcomes. Adjunctive therapy, based on modulating the host response to infection, could help to improve the 
outcomes achieved with specific anti-malarial therapy.
Results and conclusions: In the last decades, several interventions targeting different pathways have been tested. 
However, none of these strategies have demonstrated clear beneficial effects, and some have shown deleterious 
outcomes. This review aims to summarize evidence from clinical trials testing different adjunctive therapy for severe 
and cerebral malaria in humans. It also highlights some preclinical studies which have evaluated novel strategies and 
other candidate therapeutics that may be evaluated in future clinical trials.
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Background
The global burden and impact of severe malaria
Malaria is the most important parasitic disease in the 
world, causing an estimated 212 million infections and 
429,000 deaths annually [1]. The greatest burden of 
severe and fatal disease is borne by children, particularly 
in sub-Saharan Africa [1]. Humans are unable to develop 
full immunity to malaria infection. However, acquisi-
tion of clinical immunity, which confers protection from 
life-threatening malaria episodes, is possible but requires 
repeated exposure to infective mosquito bites. In areas of 
high transmission, where children are repeatedly exposed 
to infective mosquito bites from birth, most children will 
acquire clinical immunity to severe malaria (SM) if they 
survive their first years of life [2]. In areas of low trans-
mission, however, SM can occur at any age, and is more 
common among adults, because clinical immunity to 
malaria takes longer to build, is quick to wane, or simply 
never occurs. It has been argued that a decrease in the 
intensity of malaria transmission may put children and 
adults at risk of severe and fatal disease, precisely as a 
result of interfering with the natural acquisition of such 
immune responses [3].
In low-resource settings access to health services is 
often severely limited, and represents a major constraint 
to survival for those who develop SM. The case fatality 
rate (CFR) for SM is heavily dependent on the possibility 
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of reaching the health system, and can range between 
20% with in-hospital care, to  >  90% when the patient 
remains at home [4]. It has been estimated that the global 
annual incidence of SM can be as high as 2 million cases 
per year [5].
The pathobiology of severe and cerebral malaria
Both parasite and host determinants contribute to the 
onset and outcome of severe and cerebral malaria (CM). 
Host innate immune responses to infection, combined 
with the sequestration of parasitized erythrocytes (PEs) 
in the microvasculature of vital organs, such as the brain, 
result in dysregulated inflammation, endothelial activa-
tion, microvascular occlusions, metabolic derangement, 
and ultimately dysfunction and breakdown of the blood–
brain-barrier (BBB) [6]. Sequestered PEs, perfusion 
abnormalities, haemorrhages, oedema, tissue ischemia, 
and focal disruptions of the BBB are common fundo-
scopic and autopsy findings in CM patients and corre-
late well with disease severity [7–9]. Oxidative stress and 
axonal injury in the vicinity of brain haemorrhages and 
in areas of vascular occlusion have also been observed 
in CM post-mortem studies, and may contribute to neu-
rological dysfunction pre-mortem and in CM survivors 
[10–12].
There is continued debate within the malaria com-
munity as to the utility of animal models and their 
applicability to human pathophysiology. Notable dif-
ferences between human CM and Plasmodium berghei 
CM that are generally agreed upon, include the lack of 
pronounced sequestration of infected red blood cells 
(iRBCs) and the accumulation of immune cells including 
leukocytes, monocytes, macrophages, and T cells, in the 
brains of mice with experimental cerebral malaria (ECM) 
[13, 14]. In murine models of ECM, intravital microscopy 
studies have revealed that neurological signs in ECM are 
associated with vascular leakage and dysfunction of the 
neuro-immunological BBB, rather than the physiological 
BBB [15].
 Recently, endothelial protein C receptor (EPCR), a 
host receptor involved in anticoagulation and endothe-
lial cytoprotection, has been identified as a receptor for 
Plasmodium falciparum erythrocyte membrane protein 
1 (PfEMP1) suggesting a link between severe disease 
and coagulopathy [16]. In addition, dysregulation of the 
haem-haemopexin axis has been associated with poor 
clinical outcome and disease severity [17, 18]. Both of 
these new insights into SM pathogenesis open the door 
for new therapeutic options.
Primary treatment of severe and cerebral malaria
Severe malaria is a complex multi-system disease that 
may be differently defined according to the age group 
it affects, as clinical manifestations may vary between 
adults and children. However, it should be noted that the 
differences between those age groups might not be due 
to disparities in pathology but due to the under-recog-
nition of complications in young children with SM, as is 
the case for acute kidney injury [19]. For epidemiologi-
cal purposes, SM can be defined as the confirmation of 
a malarial infection in the presence of one or more of a 
series of syndromes or conditions, including impaired 
consciousness, acidosis, hyperlactataemia, hypoglycae-
mia, severe anaemia, acute kidney injury, jaundice, pul-
monary oedema, significant bleeding, hyperparasitaemia, 
or shock [5]. CM, perhaps the most feared complication 
of malaria, is characterized by severe impairment of con-
sciousness (deep coma) in the absence of other alterna-
tive explanations or diagnoses. Impaired consciousness, 
together with severe respiratory distress, has one of the 
highest mortality rates of the severe complications [5]. 
Beyond impaired consciousness, CM can also present 
with repeated seizures or other neurological abnor-
malities. CM is associated with long-term cognitive and 
neurological deficits in up to one-third of survivors, 
including hemiparesis, cerebellar ataxia, cortical blind-
ness, hypotonia, spasticity, aphasia, seizure disorders, 
behavioural disorders, and attention-deficit hyperactivity 
disorder (ADHD) [20–25].
Plasmodium falciparum is responsible for the major-
ity of malaria-associated morbidity and mortality. In 
the absence of prompt and effective treatment, P. falci‑
parum infection may progress to severe and potentially 
fatal forms. Parenteral artesunate is now widely accepted 
as the standard of care for the treatment of SM, both in 
adults and children, following the landmark SEAQUA-
MAT and AQUAMAT trials that demonstrated its supe-
riority over quinine [26, 27]. Recently, intramuscular 
artesunate administration has proven to be non-inferior 
to intravenous artesunate in reducing parasitaemia ≥ 99% 
at 24 h in children with SM [28]. However, even with the 
improved efficacy of artesunate, CFR for SM (8.5% in 
children and 15% in adults) and in particular CM (18 and 
30%, respectively) remain high [26, 27]. Therefore, treat-
ment with potent artemisinin-derivatives alone is insuf-
ficient to prevent death or neurological disability in all 
patients with SM. Adjunctive therapy, based on modu-
lating host response to infection, could reduce malaria-
associated morbidity, mortality and could enhance and 
extend the clinical utility of current anti-malarials. Gen-
eral declines of malaria and SM burden, decreases in the 
CFR for malaria and difficulties in detecting reductions 
in mortality rates may hinder the evaluation of those 
interventions due to the need of recruiting large numbers 
of patients [29]. In this respect, it is necessary to crea-
tively innovate in the design of clinical trials with more 
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precise sample sizes, more accurate clinical predictors 
and surrogate endpoints for mortality like plasma lactate 
concentration [29–31]. It is recommended that patients 
with SM with signs of serious bacterial infection receive 
intravenous antibiotics [5]. However, their effect on mor-
tality and/or clinical outcome have not been tested in any 
randomized controlled trial (RCT).
The role of adjunctive therapy in severe malaria treatment
The host immune response plays a central role in the 
onset, severity and outcome of malaria infections and 
this has promoted the search for immunomodulatory 
adjunctive therapy to improve clinical outcome. Adjunc-
tive therapy is used in combination with primary anti-
malarial treatment, with the aim of improving efficacy, 
or reducing disease-associated complications. To date, 
several types of putative adjunctive therapy have been 
tested in SM without success. Malaria immunopatho-
genesis is complex and targeting a single pathway may 
be insufficient to reduce mortality or improve neuro-
logical outcomes. Targeting multiple pathways, either 
by the use of multiple interventions (which is more 
complicated to deliver and increases the risk of adverse 
events, drug interactions and costs), or alternatively, by 
using a single intervention that targets multiple pathways 
implicated in the pathobiology of SM, could potentially 
lead to improved outcomes. Effective adjunctive therapy 
must be safe, have a clear benefit over anti-malarial use 
alone, be effective as a late-stage intervention, be mini-
mally invasive, inexpensive, and ideally feasible to imple-
ment in low-resource endemic settings, where the bulk 
of SM occurs. The objective of adjunctive therapy should 
be the improvement of clinical outcome, and/or reduc-
tion of mortality, in addition if possible of the preven-
tion of long-term neurocognitive deficits. This review 
aims to summarize recent evidence highlighting various 
approaches currently being pursued as adjunctive ther-
apy for SM and CM. The review will focus on therapy 
tested in humans in RCTs, and it will also mention some 
preclinical studies that have evaluated some novel strate-
gies and candidate therapeutics that may be evaluated in 
future clinical trials.
Search methodology
RCTs were identified through electronic searches of 
PubMed without any language or date restrictions and 
limited to humans. PubMed was searched (accessed 
15 June 2017) through the use of a broad sensitive filter 
using following combinations: “malaria AND adjunc-
tive therapy” (124 results), and “severe malaria AND 
adjunctive therapy” (81 results) and “cerebral malaria 
AND adjunctive therapy” (61 results). The references of 
the retrieved papers were used to search for additional 
studies. Adjunctive therapy assessed in RCTs is summa-
rized in Table 1. These RCTs cover a period of 33 years 
(from 1982 to 2015). Thirty-two RCTs were included in 
the Table. RCTs that did not report data on clinical out-
comes or those performed in patients without severe or 
cerebral malaria were excluded. In the text, some stud-
ies performed in uncomplicated malaria are discussed. 
Clinicaltrials.gov was also searched for ongoing RCTs or 
completed RCTs with no published data. To identify rel-
evant preclinical models PubMed was searched (accessed 
15 June 2017) using the following search terms: “experi-
mental cerebral malaria” (453 results) and “experimental 
cerebral malaria AND adjunctive therapy” (21 results). 
Studies were included if they were published after 2010, 
peripheral parasitaemia at time of adjunctive therapy 
administration was more than 5%, and the intervention 
had a benefit after the onset of symptoms.
Adjunctive therapy for the treatment of severe 
and cerebral malaria in humans
Immunomodulation
Based on the critical role of the host response in deter-
mining the onset, severity and outcome of P. falciparum 
infection, different adjunctive therapy has been evaluated 
to modify this pathophysiological pathway.
Corticosteroids With the aim of reducing swelling and 
inflammation in the brain, corticosteroids were one of 
the first treatments proposed as an adjunctive therapy 
for SM based on successful case reports. However, dexa-
methasone failed to demonstrate a decrease in mortality 
in two clinical trials testing different doses in adults with 
SM, although the small sample sizes and lack of power do 
not allow ruling out a clear effect on mortality [32–34]. 
Furthermore, one of the studies showed an increased risk 
of adverse events (prolonged coma, pneumonia and gas-
trointestinal bleeding) within the dexamethasone group 
compared to those receiving placebo [32]. No additional 
RCT have tested corticosteroids in SM, and the use of 
dexamethasone is currently not recommended in its man-
agement.
Intravenous immunoglobulin Similarly to what occurred 
with corticosteroids, treatment with intravenous immu-
noglobulin was associated with increased deleterious out-
comes compared to the placebo group, including higher 
mortality and more neurological sequelae in children [35]. 
The clinical failure of this therapy may reflect the lack of 
success to reverse cytoadherence and sequestration [35].
Curdlan sulfate Curdlan sulfate (CS), a sulfated 1 → 3-β-
d glucan, previously shown to be a potent human immu-
nodeficiency virus (HIV) entry inhibitor, and known to 
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inhibit P. falciparum in vitro, has been tested in two RCTs 
due to its capacity to modulate the immune response to 
P. falciparum [36]. As a sulfated polysaccharide (similar 
to heparin), CS would be expected to have some antico-
agulant properties, and confer certain direct and non-
specific effect on cytoadhesion and rosetting. Neither of 
the studies demonstrated differences in mortality, pos-
sibly on account of small sample sizes, but CS was safe 
and appeared to reduce the severity of the disease process 
[37].
Anti‑TNF therapy Therapy targeting tumour necrosis 
factor (TNF) and its effects have also been explored. Two 
different strategies have been evaluated in RCTs. One 
trial used monoclonal antibodies to inhibit TNF func-
tion. No difference in mortality was shown and moreo-
ver, there was an increased risk of neurological sequelae 
in the experimental group [38]. The retention of TNF by 
the antibody within the circulation may explain this del-
eterious effect [38]. Pentoxifylline (PTX), a phosphodies-
terase inhibitor, can reduce levels of TNF and has been 
tested in different studies with controversial results. Two 
studies showed an improvement in survival and a signifi-
cant reduction in coma recovery time [39, 40]. However, 
three others studies comparing adjunctive PTX treatment 
to placebo showed no clinical benefit [41–43]. One of the 
studies also showed higher than expected mortality rates 
[43]. Taking into account these data and the small samples 
of the studies, there is no clear evidence to propose PTX 
as an adjunctive therapy.
Charcoal Oral activated charcoal (oAC) can modify the 
immune response against malaria infection. In a study 
with ECM, oAC demonstrated a significant reduction in 
pro-inflammatory cytokines and improvement in survival 
[44]. Furthermore, oAC was safe and well tolerated in 
humans in a Phase I trial and did not interfere with the 
pharmacokinetics of parenteral artesunate [44]. A RCT in 
children with uncomplicated malaria to assess safety and 
parasite clearance times of oAC in combination with intra-
venous artesunate has finished in Mali but results are yet 
to be published (NCT01955382), and no trials including 
patients with SM have been conducted. Importantly, the 
route of this intervention, similarly to what occurs with 
oral medications, may prove to be a further hindrance, as 
critically ill children are unable to swallow and the use of 
nasogastric tubes may prove difficult.
PPAR‑gamma agonists Peroxisome proliferator-acti-
vated receptor-γ (PPAR-γ) agonists are attractive adjunc-
tive candidates as they modulate multiple pathways impli-
cated in the pathobiology of SM by reducing excessive 
inflammation and neurovascular leak, and by enhancing 
neuroprotective and anti-oxidant mechanisms [45–48]. 
Rosiglitazone modulates the innate host immune response 
to malaria [49]. In a murine model of ECM, this drug 
showed specific benefits by improving survival and reduc-
ing neurological impairments [48]. In a RCT in young 
adults with uncomplicated malaria, rosiglitazone was safe 
and well tolerated and those receiving rosiglitazone had 
lower levels of pro-inflammatory biomarkers and faster 
parasite clearance times [50]. Those patients receiving 
rosiglitazone also had increased levels of the considered 
“protective” brain-derived neurotrophic factor (BDNF) 
and reduced endothelial activation [48, 50]. A phase IIa 
trial to prove safety and tolerability of rosiglitazone in 
children under 12  years of age has recently concluded 
in Mozambique demonstrating the safety and good tol-
erability of rosiglitazone in children with uncomplicated 
malaria [51]. Furthermore, a phase IIb trial is now ongo-
ing at the same site to test the efficacy of rosiglitazone as 
adjuvant therapy to intravenous artesunate for improving 
clinical and neurological effects of SM (NCT02694874).
Decreasing procoagulant effects
As SM induces a procoagulant state [52], different drugs 
with anticoagulant potential (in addition to curdlan 
sulfate, already mentioned in a previous paragraph) 
have been studied as adjunctive therapy. A prospective 
randomized study in adults with uncomplicated and 
severe falciparum malaria examined acetylsalicylic acid 
and low-dose heparin [53]. Neither of these treatments 
showed beneficial effect on clinical, haemostatic or par-
asitic parameters. Sulfated glycosaminoglycans (GAG), 
including heparin and sevuparin, can disrupt rosette 
formation and inhibit cytoadherence to endothelial 
cells, and have been proposed as potential adjunctive 
therapy [54, 55]. However, only one study examined 
their effects in a RCT. Sevuparin sodium, a heparan sul-
fate mimetic, was tested in adults with uncomplicated 
malaria to determine its tolerability and pharmacoki-
netics when administered as an intravenous infusion 
in combination with atovaquone–proguanil, proving 
to be well tolerated [56]. Sevuparin reduced merozoite 
invasion as the mean relative number of ring iRBCs was 
lower in the experimental group vs the control group 
and the treatment resulted in the desequestration of 
RBC infected with mature parasites as more of these 
were detected in peripheral circulation [56].
Decreasing cytoadherence and sequestration
Levamisole is a specific alkaline-phosphatase inhibitor 
mainly used to treat intestinal helminths. It was sug-
gested as an adjunctive therapy candidate after showing 
its capacity to decrease iRBC sequestration in falcipa-
rum malaria in vivo [57]. However, a RCT in Bangladesh, 
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which explored the effect of a single levamisole hydro-
chloride dose (oral, 150 mg, single dose) in adult patients 
with SM showed no benefit compared to placebo when 
administered as adjuvant to intravenous artesunate [58]. 
As in other studies in which intravenous artesunate is 
used, its fast effect in killing P. falciparum parasites may 
have blurred the benefits of the adjuvant therapy.
Reduction of parasite biomass
Exchange blood transfusions (EBT) and erythrocyta-
pheresis have been used as an adjunctive treatment in 
SM based on the hypothesis that infusing fresh whole 
blood or uninfected erythrocytes resulting in replen-
ishing erythrocytes lost to parasitization, and reducing 
iron and other toxic bioproducts associated with infec-
tion, could lead to improved outcomes in patients with 
very high parasitaemia. To date, no prospective RCT of 
EBT or erythrocytapheresis has been conducted, and 
despite their frequent use these interventions remain 
controversial. Numerous case reports and retrospective 
studies have been conducted but there is limited evi-
dence that such approaches improve parasite clearance 
times or enhance survival in artesunate-treated patients 
[59–67]. EBT and erythrocytapheresis may be options in 
high-resource settings with cases of imported malaria, 
although current expert opinion tends not to recommend 
them as adjuvant therapy [68–70]. Such approaches, 
however, are unfeasible in resource-constrained settings 
and in communities where the prevalence of HIV and 
other blood-borne transmissible diseases is high.
Improving anaemia and liver function
Severe malarial anaemia (SMA) is an important syn-
drome of SM and is associated with increased clearance 
of infected and non-infected erythrocytes and dysregu-
lated haematopoiesis. Blood transfusions are not rou-
tinely recommended as a treatment for SMA [71–73]. 
Erythropoietin has immunomodulation effects and has 
been shown to reduce clinical signs of ECM in murine 
models, possibly in relation to its capacity to reduce neu-
ral hypoxia and cerebral pathology [74, 75]. In murine 
ECM models, erythropoietin co-administered with 
artesunate was associated with an improvement in clini-
cal recovery and global survival rates [76]. In an open-
labelled study in children with CM, erythropoietin was 
safe and well tolerated when administered with quinine 
[77]. A randomized trial of recombinant human eryth-
ropoietin (rHuEPO) in children with CM was prema-
turely stopped in Mali (EPOMAL Study; ClinicalTrials.
gov Identifier: NCT00697164), although preliminary 
data demonstrated the short-term safety of high doses of 
erythropoietin (1500 U/kg/day rHuEPO) administered 
for 3  days (NCT00697164, unpublished data, Picot S, 
pers. comm.).
Malaria-associated liver injury, including unconjugated 
hyperbilirubinemia, intrahepatic cholestasis, elevated 
serum aspartate (AST) and alanine aminotransferase 
(ALT) levels, and jaundice is not uncommon [78–80]. 
These symptoms often indicate severe illness and are 
associated with a higher incidence of complications in a 
malaria infection [80]. Ursodeoxycholic acid (UDCA) is 
used in the treatment of cholestatic liver disease and was 
tested as an adjunctive therapy in adult patients with SM 
and jaundice with the intention of improving liver func-
tion [81]. Although UDCA proved to be safe, it did not 
significantly improve liver tests. Severity of hyperbiliru-
binemia, concomitant co-infections and early treatment 
with intravenous artesunate may explain these results 
[81].
Restricting iron availability
Iron chelators such as desferrioxamine (DFO) or defer-
iprone were proposed as adjunctive therapy for malaria. 
As malaria parasites require iron to multiply, reducing 
the availability of iron could inhibit parasite replication, 
with the caveat that these agents could contribute to or 
exacerbate anaemia. A number of small RCTs, not pow-
ered to assess mortality, have evaluated the use of iron 
chelators in SM, showing a tendency to reduce coma and 
achieve faster parasite clearance times [82–84]. However, 
data remain insufficient to support the use of iron chela-
tors in the treatment of SM [85].
Prevention of seizures
In CM, seizures are usually associated with a higher 
mortality and a higher risk of neurological sequelae [5]. 
Based on this reasoning, anticonvulsants have been used 
to prevent seizures in CM. A first RCT, conducted in 
children, demonstrated that a single intramuscular injec-
tion of phenobarbitone (3.5  mg/kg) could reduce the 
incidence of convulsions, although it did not improve 
mortality [86]. A subsequent RCT in Kenya in 340 chil-
dren with CM [87], showed that a single prophylactic 
intramuscular dose of phenobarbital (20  mg/kg) could 
reduce the frequency of seizures compared to children 
receiving placebo. However, mortality was doubled in 
the group receiving phenobarbital. Respiratory depres-
sion caused by phenobarbital and is interaction with 
other intravenous anticonvulsants could explain this 
negative effect [84]. Consequently, seizure prophy-
laxis with phenobarbital could not be recommended as 
adjunctive therapy for CM and others trials with appro-
priate design, bigger sample and distinct anticonvul-
sant doses are required [88]. A recent study in Malawi, 
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assessing the effect of enteral levetiracetam vs pheno-
barbital to control acute seizures in children with CM 
has recently finished demonstrating that levetiracetam 
appeared to have a better safety profile than phenobar-
bital and a similar effect in the control of neurological 
complications and mortality (NCT01660672, unpub-
lished data, Birbeck GL, pers. comm.).
Decreasing intracranial pressure
Recent studies using magnetic resonance imaging (MRI) 
in paediatric patients from Malawi demonstrated that 
children that died from CM had increased cerebral swell-
ing, as compared to those who survived [89]. In fatal 
cases cerebral swelling progresses to respiratory arrest 
prior to death. A neuroimaging study in adult and pae-
diatric patients with CM from India showed that both 
groups had traits characteristic of posterior reversible 
encephalopathy syndrome [90]. In a RCT in Kenya, man-
nitol adjunctive therapy controlled intermediate intracra-
nial hypertension but could not prevent the development 
of intractable intracranial hypertension and did not affect 
mortality in children with CM [91]. An Ugandan RCT 
showed that one dose of mannitol had no adverse effects 
but also no impact on clinical outcomes or mortality 
in children with SM [92]. More recently, a computed 
tomography (CT) study demonstrated that brain swell-
ing is a common finding in adults with CM, although 
brain swelling did not correlate with coma depth or sur-
vival [93]. In the same study, patients were randomized 
to receive either mannitol or placebo. The group receiv-
ing mannitol showed a longer coma duration and higher 
mortality [93]. A limited understanding of the pathogenic 
mechanism leading to increase brain swelling, inadequate 
doses of mannitol and small sample sizes may explain 
these results. In light of these findings, mannitol cannot 
be recommended as adjunctive treatment for malaria.
Fluid resuscitation
Appropriate fluid management in cases of SM has been 
controversial and there is no conclusive evidence to guide 
fluid management [73, 94]. While some studies have 
proposed an important role for impaired tissue perfu-
sion in the outcomes of SM [95, 96], others have argued 
that hypovolemia does not occur in cases of severe and 
moderate malaria [97]. Some studies have explored the 
effects of fluid infusion in SM patients, and showed that 
fluid resuscitation with albumin compared with saline 
and gelofusine may reduce mortality [98, 99]. Recently, 
a large RCT (FEAST trial) was conducted in six differ-
ent centres in Africa to compare volume expansion with 
boluses of albumin or saline to standard maintenance flu-
ids in severely ill children [100]. The study was stopped 
because of higher mortality in the intervention groups. 
Fifty-seven per cent of those children had SM (1793 out 
of 3123 patients) and results in the malaria-confirmed 
cases were consistent with the larger group [100]. Excess 
of mortality seemed to be related to refractory shock 
rather than fluid overload in the boluses groups [101, 
102]. Current recommendations indicate the need to 
individually assess the volume status of each patient to 
guide treatment, a general contra-indication for colloids, 
and in children a recommendation to avoid bolus fluids 
even in case of moderate hypotension and severe dehy-
dration or metabolic acidosis [5].
Decreasing oxidative stress
Severe malaria is associated with oxidative stress that 
may be harmful due to the damaging effects of free radi-
cals on cells, increased erythrocyte rigidity and impaired 
microcirculatory flow [103, 104]. N-acetylcysteine (NAC) 
is a widely used anti-oxidant that scavenges free radicals, 
and can reduce expression of endothelial ligands in SM 
[105]. The use of NAC as adjunctive agent to reduce the 
negative aspects of oxidative stress associated with SM 
infection has been investigated. A pilot study in Thailand 
demonstrated a shorter time in normalization of lactate 
levels and Glasgow Coma Score with NAC [106]. A RCT 
in 108 adults with SM showed NAC to be safe and well 
tolerated, but to have no effect on clinical outcomes or 
mortality [107]. In a placebo-controlled  trial, intrave-
nously administered NAC had no effect on mortality or 
acidosis, and did not reduce erythrocyte rigidity in adults 
with SM [108]. Involvement of NAC in the metabolism of 
isoprostanes may have hampered is anti-oxidative effect 
[108]. Furthermore, as mentioned previously, the rapid 
action of intravenous artesunate might have blurred its 
clinical impact.
Correcting lactic acidosis
Metabolic acidosis is central to the pathophysiology of 
SM and is an independent predictor of fatality in both 
adults and children [109–112]. Dichloroacetate (DCA) 
stimulates pyruvate dehydrogenase activity and promotes 
the removal of pyruvate, the precursor of lactate. In an 
attempt to neutralize metabolic acidosis, DCA has been 
tested in small safety trials in children and adults. DCA 
was shown to reduce initial blood lactate levels, however, 
whether DCA will improve the outcome of SM remains 
to be seen [113–116].
Reduced nitric oxide bioavailability
Nitric oxide (NO) is produced from l-arginine and 
molecular oxygen by members of the nitric oxide syn-
thase (NOS) family [117]. Limited NO levels can con-
tribute to a number of pathophysiological processes 
involved in SM, including activation of the endothelium, 
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stimulation of Weibel-Palade-body exocytosis, and 
increasing the expression of endothelial adhesion mol-
ecules (ICAM-1 and VCAM-1) [118, 119]. The use of 
inhaled NO (iNO) for the treatment of SM in children 
has been investigated in two RCTs. Both studies used 
iNO, administered at 80 parts per million for 48–72  h 
and both studies used markers of endothelial activation 
as their primary endpoints, namely the rate of decrease 
of Angiopoietin-2 (Ang-2), or the rate of increase in 
Angiopoietin-1(Ang-1) [120, 121]. Both studies found 
administration of iNO to be safe, but did not observe dif-
ferences in circulating levels of Ang-1 and Ang-2 between 
treatment arms. It is possible that the dose and/or route 
of administration of NO was unable to cause a measur-
able effect on the endothelium or perhaps it is more 
suitable in the treatment of patients with increased cer-
ebrovascular resistance [120, 121]. Alternative methods 
to increase NO levels, such as increasing plasma l-argi-
nine levels via intravenous administration or increasing 
the bioavailability of cofactors required for NOS activity 
remain plausible interventions for adjunctive treatments 
[122–124].
Novel strategies for adjunctive therapy delivery (preclinical 
murine models)
Animal models remain an useful tool to investigate 
novel adjunctive therapy [13]. Despite the large volume 
of research in experimental murine models, this discus-
sion will be limited to preclinical studies where improve-
ments have been observed in relation to novel treatments 
administered at the onset of clinical symptoms in ECM, 
and exclude studies of prophylactic treatment. This prob-
ably best resembles a clinical scenario where patients 
with severe disease seek treatment. Studies where 
adjunctive interventions have shown to protect against 
ECM-induced neurocognitive impairment will also be 
discussed (Table 2).
Immunomodulation
New strategies to modify the immune response and tar-
get different pathways are ongoing. A recent study in 
ECM tested a new formulation of glucocorticosteroid, 
whereby β-methasone hemisuccinate (BMS) was encap-
sulated in lipososomes. Encapsulated BMS was less 
toxic to mice than the unencapsulated drug, and when 
Table 2 Adjunctive therapy administered after the onset of neurological symptoms of ECM
CQ chloroquine, ECM experimental cerebral malaria, i.m. intramuscular, IV intravenous, NO nitric oxide, s.c. subcutaneous, SM severe malaria, UM uncomplicated 
malaria
Author, year, reference Adjuvant Therapy Route of administration Outcome of treatment administered 
after neurological symptoms
Inmunomodulation
 Waknine-Grinberg et al. 2013, [124] Glucocorticosteroids in liposomes i.v. injection Improved survival, prevented ECM symp-
toms, improved clinical scores
 Dende et al. 2015, [127] Curcumin oral gavage Improved survival, reduced parasitemia
Neuroprotection
 Dai et al. 2012, [129] Lithium chloride injection (route not described) Prevention of cognitive and motor 
deficits. Reduced long-term motor 
coordination impairment. No effect on 
survival or parasitemia
 Cabrales et al. 2010, [130] Nimodipine i.p. injection Improved survival, improved motor score, 
reduced pial vasoconstriction
 Martins et al. 2013, [132] Nimodipine s.c. osmotic pumps Improved survival, reduced BBB dysfunc-
tion, reduced inflammation
Delivering gaseous signaling
 Orjuela-Sanchez et al. 2013, [133] Glyceryl trinitrate Transdermal patch Improved survival, reversal of pial arteri-
olar vasoconstriction
Improving endothelial function
 Higgins et al. 2016 [140] Recombinant human Ang-1 s.c. injection Improved survival, prevents worsening of 
clinical outcomes, reduced cerebrovas-
cular leak
 Wilson et al. 2013, [141] Atorvastatin i.p. injection Improved survival, reduced systemic 
and cerebral inflammation, reduces 
endothelial activation and reduced 
cerebrovascular leak
 Dwivedi H et al. 2016, [145] Vitamin D i.m. injection Improved survival, reduced cerebrovas-
cular leak, reduced inflammation
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administered at a late stage of infection it improved sur-
vival and prevented the development and progression of 
the cerebral syndrome [125]. These preclinical studies 
may lead to the use of new steroids for the treatment of 
SM.
Curcumin is an anti-inflammatory molecule that scav-
enges reactive oxygen and nitrogen species [126]. In vitro 
studies have shown that curcumin has additive anti-para-
sitic activity when used in combination with artemisinins 
[127]. When administered in combination with arteether 
to mice showing symptoms of CM, curcumin improved 
survival and prevented death due to anaemia [128].
Neuroprotection
Preclinical models have investigated lithium as a poten-
tial neuroprotective intervention. Lithium has been pro-
posed to act as a neuroprotective agent by its ability to 
inhibit glycogen synthase kinase 3 (GSK3β), activate the 
PI3 K/Akt and MAPK signalling pathways, and by induc-
ing the expression of brain-derived neurotrophic factors 
in neurons [129]. Lithium chloride administered to mice 
with ECM significantly increased the activation of Akt, 
which was associated with the prevention of adverse neu-
rocognitive outcomes. Adjunctive treatment with lithium 
chloride was associated with better spatial and visual 
memory, and motor coordination in mice recovering 
from ECM [130].
Nimodipine is a calcium channel blocker that has been 
shown to prevent vasospasms, the abnormal physical 
narrowing of arteries in the sub-arachnoid space. Neu-
ropathological features of CM include haemorrhages in 
the brain parenchyma [8]. It has been reported that mice 
with ECM show vasoconstriction and blood flow changes 
in the pia matter of the brain. Adjunctive treatment with 
nimodipine, when administered during late-stage infec-
tion, improved survival and improved blood flow to the 
brain [131]. However, potential hazards, such as hypoten-
sion, bradycardia and death can occur in humans treated 
with high doses of nimodipine [132]. Experiments have 
shown that in ECM, slow continuous administration 
of adjunctive nimodipine did not increase hypotension 
[133]. Additional preclinical work is required to deter-
mine if nimodipine is an attractive candidate as adjunc-
tive therapy in SM.
Delivering gaseous signalling molecules
Increasing bioavailable NO in CM remains an attrac-
tive treatment strategy. A transdermal nitroglycerin 
patch was tested as an adjunctive therapy in late-stage 
ECM, where it increased plasma nitrate and nitrite lev-
els (with no effect on blood pressure), and was associ-
ated with improved survival [134]. Haem oxygenase-1 
(HO-1) catalyzes the degradation of haem and its activity 
has been shown to protect mice from ECM [135]. Pro-
phylactic inhalation of carbon monoxide (CO), an end-
product of this catalysis, prevents mice from developing 
ECM and malaria-associated acute lung injury [135, 136]. 
The toxicity of inhaled CO limits its clinical utility. How-
ever, CO-releasing molecules that can deliver controlled 
amounts of CO to tissues are valid alternatives [137]. The 
CO-releasing molecule ALF492 significantly improved 
survival in ECM when administered with artesunate 
beyond the anti-malarial alone and without affecting oxy-
gen transport by haemoglobin [138].
Improving endothelial function
Targeting endothelial activation and preventing micro-
vascular permeability and vascular leak in CM is another 
potential target for adjunctive therapy [139]. The angi-
opoietin (Ang)-Tie2 axis critically regulates endothelial 
cell function [140]. Perturbation of Ang-1, Ang-2 and 
soluble Tie2 concentrations are associated with disease 
severity and death in CM in both murine models and 
human infections [141]. A mechanistic role for the Ang-
Tie2 axis was established in ECM, where it was shown 
that Ang-1-deficient mice were more susceptible to ECM 
and adjunctive administration of a recombinant Ang-1 
construct preserved BBB integrity and improved survival 
beyond artesunate monotherapy alone [141]. These stud-
ies provide preclinical evidence that interventions that 
target the Ang-Tie2 axis are potential adjunctive therapy 
for SM.
Atorvastatin, a drug that reduces cholesterol levels, also 
inhibits the expression of CXCL10, high levels of which 
have been associated with CM mortality in adult patients 
[142]. Mice deficient in CXCL10 are partially protected 
against ECM [143] and mice receiving atorvastatin treat-
ment in addition to artemether upon neurological signs 
of ECM had improved survival, and increased transcrip-
tion of Ang-1 and reduced levels of Ang-2 in brain tissues 
[144].
Vitamin D may improve survival by targeting multi-
ple pathways in both the innate and acquired immune 
systems [145]. One study showed that simultaneous 
administration of intramuscular arteether and vitamin D 
to mice at the onset of neurological symptoms of ECM 
improved survival. This survival was accompanied by 
reduced BBB leak and reduced levels of circulating pro-
inflammatory cytokines [146].
Inhibition of the angiotensin pathway is another strat-
egy to maintain endothelial integrity by preserving inter-
endothelial cell junctions. Blocking the angiotensin II 
type 1 receptor with Irbesartan or activation of the type 2 
receptor with compound 21 in combination with chloro-
quine resulted in an increased survival rate, higher than 
when treated with the anti-malarial alone, even when 
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mice were treated at the onset of neurological symptoms 
[147].
Conclusions
Malaria remains a major global health problem, asso-
ciated with high morbidity and mortality. Strategies 
designed to improve early detection and recognition of 
cases likely to progress towards to severe disease, so as 
to trigger immediate treatment, are absolutely neces-
sary. For those individuals who progress to severe forms 
of the disease despite prompt treatment, new tools are 
needed to improve outcomes in addition to existing 
anti-malarials. Preventing long-term sequelae, such as 
improving neurocognitive outcomes in SM survivors, 
should be an important consideration when it comes to 
potential adjunctive therapy; however so far, the major-
ity of attempts to enhance the efficacy of anti-malarial 
drugs with adjunctive therapy have failed. The develop-
ment of adjunctive therapy would benefit from a more 
complete understanding of the physiopathology of SM 
and CM, and how it differs between adults and chil-
dren. The identification of host biomarkers associated 
with disease severity and host response to treatment 
could provide a useful read out of therapeutic efficacy, 
and empower RCTs to evaluate adjunctive therapy with 
smaller and better defined cohorts. Therapy tested in 
preclinical models of SM are still a valuable resource for 
potential adjunctive therapy; however preclinical models 
should employ scenarios as similar as possible to clinical 
practice, targeting the onset of clinical disease symptoms 
and prevention of long-term sequelae. RCTs in humans 
should also be guided by a rational and good design based 
on well-defined sample sizes, clinical predictors and 
study endpoints that permit detection of significant dif-
ferences in SM outcomes and direct comparison between 
studies. It is difficult to extrapolate conclusions and con-
ceive future research considering the heterogeneity of the 
RCTs in terms of anti-malarial used, type of malaria (SM 
and/or CM, coma), or study characteristics (limited num-
ber of patients per study, different and no comparable age 
of the populations, different treatment doses, studies not 
designed to identify differences in clinical outcomes or 
mortality). Further research, with promising candidates 
that surpass previous constraints of earlier studies, is 
urgently needed in order to accelerate the identification 
of new adjunctive therapy for the treatment of SM.
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